News & Updates

Sotatercept increases exercise tolerance in PAH

Patients with pulmonary arterial hypertension treated with sotatercept demonstrate improved exercise tolerance, driven in part by increased haemoglobin, according to a study.

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

Treatment with dexamethasone eye drops is safe and may reduce the need for invasive treatment in preemies with type 1 retinopathy of prematurity (ROP), according to the DROPROP study.

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

Treatment with STRIDE*, with or without lenvatinib, plus TACE** significantly improves progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) in patients with embolization-eligible hepatocellular carcinoma (eeHCC) compared with TACE alone, according to the phase III EMERALD-3 trial presented at ESMO GI 2026.

Add-on high-dose vitamin D3 of little benefit in mCRC

Adding high-dose vitamin D3 to standard chemotherapy does not appear to improve outcomes in patients with previously untreated metastatic colorectal cancer (mCRC), as shown in a phase III trial.

IVF treatment linked to mental health vulnerability

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Treatment with the oral orexin receptor 2 (OX2R) agonist oveporexton improves symptom control, daily function, and cognitive outcomes in patients with narcolepsy type 1, according to pooled data from two phase III studies, The First Light and The Radiant Light.

Ipilimumab plus nivolumab elicits response in patients with rare cancer

Combination treatment with ipilimumab and nivolumab yields meaningful response among patients with multiple refractory rare cancer types, according to a phase II trial.

Inhaled levodopa helps manage off episodes in PD, regardless of age

Treatment with the inhaled levodopa formulation CVT-301 provides rapid motor symptom relief during off periods, with consistent efficacy seen across Parkinson’s disease (PD) patients of all ages, according to a post hoc analysis of three phase III trials.